Here is the design of a clinical trial:

Official Title: Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial

Included conditions:
- Pancreatic Neoplasms

Study Armgroups:
- {'label': 'SBRT with concurrent chemotherapy', 'type': 'EXPERIMENTAL', 'description': 'SBRT with nab-Paclitaxel plus Gemcitabine (nab-P+Gem) chemotherapy', 'interventionNames': ['Drug: nab-Paclitaxel+Gemcitabine', 'Radiation: split-course SBRT']}

Interventions:
- {'type': 'DRUG', 'name': 'nab-Paclitaxel+Gemcitabine', 'description': 'Drug: nab-Paclitaxel 125 mg/m2 IV over approximately 30-45 min on Days 1 and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 min on Days 1 and 15 of each 28-day cycle for 6 cycles.', 'armGroupLabels': ['SBRT with concurrent chemotherapy']}
- {'type': 'RADIATION', 'name': 'split-course SBRT', 'description': 'Radiation: During the first 1 and 2 cycles of chemotherapy, SBRT was given as a single irradiation of 10 Gy ⅹ 4 times (Days 2 and 16 of each 28-day cycle).', 'armGroupLabels': ['SBRT with concurrent chemotherapy']}

Primary Outcomes:
- {'measure': 'Kaplan-Meier Estimate of Progression-Free Survival (PFS)', 'description': 'Progression-free Survival (PFS) was defined as the time from the date of the first dose to the date of disease progression or death (by any cause), whichever is earlier. The analysis day was calculated from enrollment date for one participant who was not treated. Participants who have no disease progression or have not died were censored to last tumor assessment date with progression-free.', 'timeFrame': 'From enrollment to 2 years after the end of treatment'}

Please estimate the sample size based on the assumption: 
The sample size calculation assumes a one-sided alpha of 0.05, 80% power, a 10% dropout rate, and a minimum follow-up period of 1 year. Statistical normality for continuous variables will be assessed, and comparisons will be performed using analysis of variance or non-parametric equivalents. Categorical data will be compared using chi-squared tests or Fisher's exact tests. OS and PFS curves will be plotted using the Kaplan-Meier method, and the log-rank test will be used for comparisons. Proportional hazard Cox regression will be used when necessary. Data analysis will be performed on both intention-to-treat and per-protocol basis, with a significance level of 0.05 for all p values.
Sample size and statistical analysis
        The primary endpoint for this study is the median PFS. The null (Ho) and alternative (Ha) hypotheses for this endpoint are as follows, where M is the median PFS and 6.8 months is the median PFS based on the data of our research centre and the previous research reports25 28â30: Ho: Mâ¤6.8 Ha: M>6.8.
        A total sample size of 27 subjects will have 80% power to detect an increase in the median PFS of 6.8â12 months. The sample size is calculated assuming a one-sided alpha of 0.05 that subjects will be enrolling for 24 months, and that each subject will be followed up for a minimum of 1âyear. Twenty-seven subjects will be enrolled assuming a 10% drop-out rate.
        For continuous variables, statistical normality will be first assessed. Comparisons between these main effects will be then performed by analysis of variance or its two non-parametric equivalents as appropriate. Categorical data will be compared by Ï2 tests or Fisherâs exact tests. The OS and PFS curves will be plotted by the Kaplan-Meier method. The log-rank test will be employed for comparisons of OS and PFS. Proportional hazard Cox regression adjusted for variables will be used when necessary. Data analysis will be performed on both intention-to-treat and per-protocol basis. All p values will be reported using a significance level of 0.05.